Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) Stock Has Average Target Price of $52.83 According to Brokerages

Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) has received an average rating of “Moderate Buy” from the seven brokerages that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation and six have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $52.83.

Several analysts have recently weighed in on PTHS shares. Zacks Research downgraded Pelthos Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Wednesday, October 7th. Lake Street Capital dropped their target price on Pelthos Therapeutics from $50.00 to $40.00 and set a “buy” rating on the stock in a research report on Monday, October 12th. Finally, Oppenheimer cut their price target on Pelthos Therapeutics from $66.00 to $64.00 and set an “outperform” rating on the stock in a research note on Friday, August 14th.

Institutional Investors Weigh In On Pelthos Therapeutics

An institutional investor recently raised its stake in Pelthos Therapeutics stock. Knott David M Jr boosted its holdings in shares of Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) by 9.3% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 21,073 shares of the company’s stock after purchasing an additional 1,792 shares during the quarter. Knott David M Jr owned approximately 0.63% of Pelthos Therapeutics worth $443,000 at the end of the most recent quarter. Institutional investors and hedge funds own 77.96% of the company’s stock.

Pelthos Therapeutics Stock Performance

Pelthos Therapeutics stock opened at $20.15 on Friday. Pelthos Therapeutics has a 12-month low of $18.19 and a 12-month high of $37.50. The company has a market capitalization of $77.17 million, a price-to-earnings ratio of -0.92 and a beta of 3.07. The company has a debt-to-equity ratio of 3.40, a current ratio of 1.98 and a quick ratio of 1.31. The firm’s fifty day moving average price is $23.45 and its 200 day moving average price is $25.07.

Pelthos Therapeutics (NYSEAMERICAN:PTHS) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($6.62) EPS for the quarter. The firm had revenue of $15.60 million during the quarter. Pelthos Therapeutics had a negative return on equity of 204.71% and a negative net margin of 165.24%. On average, research analysts forecast that Pelthos Therapeutics will post -15.22 EPS for the current fiscal year.

About Pelthos Therapeutics

Pelthos Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for pain management. The company’s work is centered on addressing unmet needs in the treatment of acute and chronic pain, including the development of potential alternatives to traditional opioid-based medicines.

Pelthos Therapeutics is advancing investigational drug candidates through preclinical and clinical development. As with other clinical-stage biotechnology companies, its products remain subject to testing and regulatory review, and there is no assurance that any candidate will receive approval or become commercially available.

Publicly available information about the company’s specific product pipeline, operating history, geographic reach and leadership is limited.